Luke Walker

Dr. Walker joined Harpoon Therapeutics in October 2022 with over 15 years of clinical practice, research and drug development experience. Dr. Walker most recently served as Vice President of Clinical Development at Seagen Inc., where he oversaw multiple early-stage clinical programs. He was also responsible for leading TUKYSA® (tucatinib) through successful approval and commercial launch in HER2-positive metastatic breast cancer as Global Development Lead and worked on tucatinib’s early-stage development at Cascadian Therapeutics Inc., which was acquired by Seagen. Prior to his career in clinical drug development, Dr. Walker practiced for several years as a medical oncologist and served as Principal Investigator in numerous Phase 2 and Phase 3 clinical trials. Dr. Walker received his medical degree from the University of Oklahoma Health Sciences Center and completed his fellowship training in Hematology and Medical Oncology at Oregon Health Sciences University.